- Book学术

发布求助

文献互助智能选刊最新文献

IF 29.5 1区医学 Q1 HEMATOLOGY

Journal of Hematology & Oncology Pub Date : 2025-03-05 DOI:10.1186/s13045-025-01674-6

Na Li, Jianpeng Sheng, Hong-Hu Zhu

引用次数: 0

摘要

降解剂疗法因其靶向和消除恶性肿瘤相关蛋白的创新方法而备受关注，有望改善复发或难治性（R/R）血液恶性肿瘤患者的预后，尤其是白血病、非霍奇金淋巴瘤和多发性骨髓瘤患者的预后。目前，基于降解剂开发的主要类别包括分子胶（如 Cemsidomide、NX-5948）、PROTACs（如 BGB-16673、AC-676、KT-333）和 RNA 降解剂（如 SKY-1214）。这篇通讯总结了在 ASH 2024 年会上介绍的降解剂疗法的临床前和临床最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024

Degrader therapies have garnered significant attention for their innovative approach to targeting and eliminating malignancy-associated proteins, holding promise for improving outcomes for patients with relapsed or refractory (R/R) hematological malignancies, especially in cases of leukemia, non-Hodgkin lymphoma, and multiple myeloma. Currently, the main categories developed based on degraders include molecular glue (such as Cemsidomide, NX-5948), PROTACs (such as BGB-16673, AC-676, KT-333 ), and RNA degraders (such as SKY-1214). This correspondence summarizes the preclinical and clinical updates on degrader therapies presented at the ASH 2024 annual meeting.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Hematology & Oncology 医学-血液学

CiteScore

48.10

自引率

2.10%

发文量

169

审稿时长

6-12 weeks

期刊介绍： The Journal of Hematology & Oncology, an open-access journal, publishes high-quality research covering all aspects of hematology and oncology, including reviews and research highlights on "hot topics" by leading experts. Given the close relationship and rapid evolution of hematology and oncology, the journal aims to meet the demand for a dedicated platform for publishing discoveries from both fields. It serves as an international platform for sharing laboratory and clinical findings among laboratory scientists, physician scientists, hematologists, and oncologists in an open-access format. With a rapid turnaround time from submission to publication, the journal facilitates real-time sharing of knowledge and new successes.